Last reviewed · How we verify
GSK1838262 Extended Release Tablets
GSK1838262 is a selective inhibitor of sodium-dependent glucose cotransporter 1 (SGLT1) that reduces intestinal glucose absorption.
GSK1838262 is a selective inhibitor of sodium-dependent glucose cotransporter 1 (SGLT1) that reduces intestinal glucose absorption. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | GSK1838262 Extended Release Tablets |
|---|---|
| Also known as | XP13512, gabapentin enacarbil |
| Sponsor | XenoPort, Inc. |
| Drug class | SGLT1 inhibitor |
| Target | SGLT1 (sodium-glucose cotransporter 1) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SGLT1 is responsible for active glucose transport across the intestinal epithelium. By inhibiting SGLT1, GSK1838262 decreases postprandial glucose levels and overall glucose absorption. This mechanism is distinct from SGLT2 inhibitors, which work primarily in the kidney, and may provide therapeutic benefit in glycemic control with a different safety profile.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disorders (diarrhea, nausea)
- Osmotic diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK1838262 Extended Release Tablets CI brief — competitive landscape report
- GSK1838262 Extended Release Tablets updates RSS · CI watch RSS
- XenoPort, Inc. portfolio CI